A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
NKTR-181 is being developed as an analgesic compound for the treatment of moderate to severe
chronic pain - active as a mu agonist, but with inherent molecular properties designed to
provide a unique clinical profile, including most notably, reduced CNS side effects and an
attenuated attractiveness as a target of abuse.